Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
de Galiza Barbosa, F., Queiroz, M. A., Nunes, R. F., Costa, L. B., Zaniboni, E. C., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00300-7 · Cited by 288
Nuclear medicine and molecular imaging advances in the 21st century
Vaz, S. C., Oliveira, F., Herrmann, K., & Veit-Haibach, P. (2020) · The British Journal of Radiology · doi:10.1259/bjr.20200095 · Cited by 86
Werner, R. A., Bundschuh, R. A., Bundschuh, L., Javadi, M. S., Leal, J. P., Higuchi, T., Pienta, K. J., Buck, A. K., Pomper, M. G., Gorin, M. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217588 · Cited by 55
Self-citationImaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Salas Fragomeni, R. A., Amir, T., Sheikhbahaei, S., Harvey, S. C., Javadi, M. S., Solnes, L. B., Kiess, A. P., Allaf, M. E., Pomper, M. G., Gorin, M. A., & Rowe, S. P.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2018-03-15
- Volume
- 59
- Issue
- 6
- Pages
- 871-877
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2789747592
- Cited by
- 156
- References
- 1
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. https://app.cochat.ai/papers/10.2967/jnumed.117.203570
- The paper
- Salas Fragomeni, R. A., Amir, T., Sheikhbahaei, S., Harvey, S. C., Javadi, M. S., Solnes, L. B., Kiess, A. P., Allaf, M. E., Pomper, M. G., Gorin, M. A., & Rowe, S. P. (2018). Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.203570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.